Atrial Septal Defect Market Rising Demand, Evolving Trends, Future Perspectives, Size, Share And Forecast To 2033

The new report published by The Business Research Company, titled Atrial Septal Defect Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the atrial septal defect market size has grown strongly in recent years. It will grow from $3.85 billion in 2023 to $4.14 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%. The atrial septal defect market size is expected to see strong growth in the next few years. It will grow to $5.6 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=16345&type=smp

Growing Prevalence of Congenital Heart Defects (CHD) Drive Atrial Septal Defect Market Expansion
The prevalence of congenital heart defects (CHD) is expected to propel the growth of the atrial septal defect market going forward. Congenital heart defects refer to structural abnormalities in the heart present at birth. The increasing prevalence of congenital heart defects refers to the growing number of individuals diagnosed with structural heart abnormalities present from birth. Atrial septal defect treatment helps manage congenital heart defects by correcting abnormal blood flow between the heart's chambers, improving overall heart function, and reducing associated complications. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based national agency, in Australia, approximately 65,000 children and adults are living with congenital heart disease. In the 2020-21 period, there were about 5,900 hospitalizations where congenital heart disease was the primary diagnosis, accounting for 79 deaths in infants under one year old, representing 7.8% of all infant deaths. Therefore, the prevalence of congenital heart defects will drive the atrial septal defect market.

Advancements In Occluders For Arterial Septal Defect Treatment
Major companies operating in the arterial septal defect market are developing advanced devices and seeking approval to increase their availability and uses. Device approval refers to obtaining official authorization or certification for a device, typically from a regulatory body or relevant authority, before it can be legally manufactured, sold, or used in a specific market or for a particular purpose. For instance, in March 2024, Occlutech GmbH, a Sweden-based specialist provider of minimally invasive cardiac devices, announced that the United States Food and Drug Administration (FDA) had approved the Occlutech ASD Occluder and Occlutech Pistol Pusher for treating atrial septal defects (ASD). This approval marks a significant milestone for the company, which has been working to advance healthcare globally. The Occlutech ASD Occluder is designed to be a lifelong solution for patients with echocardiography-confirmed defects. It is a self-expanding nitinol device that includes two flexible discs attached to both sides of the patient's atrial septum using the Occlutech Pistol Pusher. With this approval, Occlutech will begin commercialization in the US through an exclusive partnership with B. Braun Interventional Systems.

The atrial septal defect market covered in this report is segmented -

1) By Treatment Procedure: Surgical Closure, Transcatheter Closure, Hybrid Procedures, Medication Therapy
2) By Diagnosis: Chest X-Ray, Electrocardiogram, Cardiac Catheterization, Transesophageal Echocardiography, Pulse Oximetry
3) By Product Type: Medical Devices, Pharmaceutical Products
4) By Age Group: Pediatric, Adult
5) By End-User: Hospitals, Ambulatory Surgical Centers, Cardiac Clinics, Other End-Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=16345&type=discount

Major companies operating in the atrial septal defect market are Abbott Laboratories, Medtronic plc, Siemens Healthineers, Boston Scientific Corporation, Philips Healthcare, Edwards Lifesciences Corporation, W. L. Gore & Associates Inc., St. Jude Medical LLC, Cook Medical, Lepu Medical Technology Co. Ltd., MicroPort Scientific Corporation, Lifetech Scientific Corporation, Venus Medtech Hangzhou Inc, Occlutech Holding AG, Cohere*x Medical, Osypka AG, Arjo AB, Heart Medical Europe BV, AtriCure Inc., Asklepion Pharmaceuticals LLC

Contents of the report:
1. Executive Summary
2. Atrial Septal Defect Market Report Structure
3. Atrial Septal Defect Market Trends And Strategies
4. Atrial Septal Defect Market - Macro Economic Scenario
5. Atrial Septal Defect Market Size And Growth
…..
27. Atrial Septal Defect Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/atrial-septal-defect-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.